ANGPTL3/8 antibody - Eli Lilly and Company
Latest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antibodies; Antihyperglycaemics; Cardiovascular therapies
- Mechanism of Action Angiogenic protein modulators; ANGPTL3 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Diabetes mellitus
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Cardiovascular-disorders in USA (Parenteral)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Diabetes-mellitus in USA (Parenteral)
- 11 Apr 2022 ANGPTL3/8 antibody licensed to Kyttaro worldwide